LIVALO

This brand name is authorized in Brazil, Japan, Singapore, United States

Active ingredients

The drug LIVALO contains one active pharmaceutical ingredient (API):

1 Pitavastatin
UNII IYD54XEG3W - PITAVASTATIN CALCIUM

Pitavastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the biosynthesis of cholesterol, and inhibits cholesterol synthesis in the liver.

Read about Pitavastatin

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
LIVALO Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
C10AA08 Pitavastatin C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AA HMG CoA reductase inhibitors
Discover more medicines within C10AA08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 507612110017502, 507612110017602, 507612110017802
Country: JP 医薬品医療機器総合機構 Identifier(s): 2189016F1028, 2189016F2024, 2189016F3020, 2189016F4027, 2189016F5023, 2189016F6020
Country: SG Health Sciences Authority Identifier(s): 15859P, 15860P
Country: US FDA, National Drug Code Identifier(s): 66869-104, 66869-204, 66869-404

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.